(MEDX) Horizon Kinetics Medical - Ratings and Ratios

Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US53656G5633

Biotech, Pharmaceuticals, Medical Equipment, Medical Devices, Healthcare

Description: MEDX Horizon Kinetics Medical

The fund is an actively-managed exchange-traded fund ('ETF') that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.

Additional Sources for MEDX ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

MEDX ETF Overview

Market Cap in USD 15m
Category Health
TER 0.85%
IPO / Inception 1999-09-30

MEDX ETF Ratings

Growth Rating -26.4
Fundamental -
Dividend Rating 1.0
Rel. Strength -18.4
Analysts -
Fair Price Momentum 24.00 USD
Fair Price DCF -

MEDX Dividends

Dividend Yield 12m 1.82%
Yield on Cost 5y 1.73%
Annual Growth 5y -44.71%
Payout Consistency 76.3%
Payout Ratio %

MEDX Growth Ratios

Growth Correlation 3m 76.8%
Growth Correlation 12m -76.5%
Growth Correlation 5y -15.4%
CAGR 5y -1.61%
CAGR/Max DD 5y -0.07
Sharpe Ratio 12m 0.33
Alpha -17.99
Beta 0.678
Volatility 13.36%
Current Volume 9.1k
Average Volume 20d 0.7k
Stop Loss 26.9 (-3.3%)
What is the price of MEDX shares?
As of July 12, 2025, the stock is trading at USD 27.83 with a total of 9,102 shares traded.
Over the past week, the price has changed by +2.25%, over one month by +2.78%, over three months by +12.31% and over the past year by -7.51%.
Is Horizon Kinetics Medical a good stock to buy?
Probably not. Based on ValueRay´s Analyses, Horizon Kinetics Medical (NASDAQ:MEDX) is currently (July 2025) not a good stock to buy. It has a ValueRay Growth Rating of -26.38 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MEDX is around 24.00 USD . This means that MEDX is currently overvalued and has a potential downside of -13.76%.
Is MEDX a buy, sell or hold?
Horizon Kinetics Medical has no consensus analysts rating.
What are the forecasts for MEDX share price target?
According to our own proprietary Forecast Model, MEDX Horizon Kinetics Medical will be worth about 27.4 in July 2026. The stock is currently trading at 27.83. This means that the stock has a potential downside of -1.51%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 27.4 -1.5%